Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MMP1 | P03956 | 4/20 | 0.41 |
| ▸ | MMP9 | P14780 | 4/20 | 0.41 |
| ▸ | MMP13 | P45452 | 4/20 | 0.41 |
| ▸ | ADAM17 | P78536 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.40 |
| ▸ | CCR5 | P51681 | 2/20 | 0.39 |
| ▸ | CCR3 | P51677 | 1/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.38 |
| ▸ | OPRL1 | P41146 | 3/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2942975 | 0.88 | SIGMAR1 (0.48) | MMP1MMP9MMP13ADAM17MEN1 | |
| SCHEMBL2913042 | 0.88 | CCR8 (0.42) | ALDH1A1MMP1MMP9MMP13ADAM17 | |
| SCHEMBL2449271 | 0.83 | KDM4E (0.54) | ALDH1A1MEN1POLBKMT2AMCHR1 | |
| SCHEMBL2915758 | 0.83 | CCR8 (0.42) | ALDH1A1MMP1MMP9MMP13ADAM17 | |
| SCHEMBL2915457 | 0.82 | HSD17B10 (0.39) | ALDH1A1MEN1KMT2ASIGMAR1 | |
| SCHEMBL2909202 | 0.82 | KCNA5 (0.36) | ALDH1A1MMP1MMP9MMP13ADAM17 | |
| SCHEMBL2912440 | 0.81 | HTR1A (0.41) | ALDH1A1MMP1MMP9MMP13ADAM17 | |
| SCHEMBL2449927 | 0.81 | CCR8 (0.52) | ALDH1A1MEN1KMT2AMCHR1OPRM1 | |
| SCHEMBL2918586 | 0.81 | MCHR1 (0.37) | ALDH1A1MCHR1 | |
| SCHEMBL2915410 | 0.80 | MEN1 (0.45) | ALDH1A1MMP1MMP9MMP13ADAM17 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1979355-B1 | SPIRO IMIDAZOLE DERIVATIVES AS PPAR MODULATORS | IRM LLC (BM) | 2010-08-18 | — | — | EP | claimed |
| US-20090137610-A1 | SPIRO IMIDOZOLE DERIVATIVES AS PPAR MODULATORS | IRM LLC (BM) | 2009-05-28 | — | — | US | claimed |
| EP-1979355-A1 | SPIRO IMIDAZOLE DERIVATIVES AS PPAR MODULATORS | IRM LLC (BM) | 2008-10-15 | — | — | EP | claimed |
| WO-2007087448-A1 | SPIRO IMIDAZOLE DERIVATIVES AS PPAR MODULATORS | IRM LLC (BM) | 2007-08-02 | — | — | WO | claimed |
| EP-1979355-B1 | SPIRO IMIDAZOLE DERIVATIVES AS PPAR MODULATORS | IRM LLC (BM) | 2010-08-18 | — | — | EP | disclosed |
| EP-1979355-B1 | SPIRO IMIDAZOLE DERIVATIVES AS PPAR MODULATORS | IRM LLC (BM) | 2010-08-18 | — | — | EP | disclosed |
| US-20090137610-A1 | SPIRO IMIDOZOLE DERIVATIVES AS PPAR MODULATORS | IRM LLC (BM) | 2009-05-28 | — | — | US | disclosed |
| US-20090137610-A1 | SPIRO IMIDOZOLE DERIVATIVES AS PPAR MODULATORS | IRM LLC (BM) | 2009-05-28 | — | — | US | disclosed |
| US-20090137610-A1 | SPIRO IMIDOZOLE DERIVATIVES AS PPAR MODULATORS | IRM LLC (BM) | 2009-05-28 | — | — | US | disclosed |
| WO-2007087448-A1 | SPIRO IMIDAZOLE DERIVATIVES AS PPAR MODULATORS | IRM LLC (BM) | 2007-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137610-A1 | SPIRO IMIDOZOLE DERIVATIVES AS PPAR MODULATORS | PPARD, PPARG, PPARA | ALDH1A1 736/4885MMP1 3112/4885MMP9 4212/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.